Casado, I. (Itziar)

Filtering

20183

Settings

Author search.filters.isAuthorOfPublication.a13873f4-c23d-450a-8a5d-aba7c0f533ac

Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    Interim efecctiveness of trivalen influenza vaccine in a Seaton dominated by lineage mismatched influenza B, northern Spain, 2017/18.
    (Eurosurveillance, 2018) Martínez-Baz, I. (Iván); Navascués, A. (Ana); Pérez-García, A. (Alejandra); Ezpeleta, G. (Guillermo); Aguinaga, A. (Aitziber); Castilla, J. (Jesús); Pozo, F. (Francisco); Casado, I. (Itziar); Ezpeleta, C. (Carmen)
    The 2017/18 interim estimate of trivalent influenza vaccine effectiveness (VE) was 39% (95% confidence interval: 20-54) in Navarre. Compared with individuals unvaccinated in the current and five previous seasons, VE against influenza B was 41% for current and any prior doses, 67% for current vaccination only, and 22% for any prior doses, and 43%, 51% and 54%, respectively against influenza A(H3N2). This suggests moderate VE despite predominance of lineage mismatched influenza B.
  • Thumbnail Image
    Progress in the elimination of hepatitis C virus infection in Spain: a population-based cohort study
    (Public Library of Science, 2018) San-Miguel, R. (Ramon); Martínez-Baz, I. (Iván); Pérez-García, A. (Alejandra); Burgui, C. (Cristina); Goñi-Esarte, S. (Silvia); Repáraz, J. (Jesús); Aguinaga, A. (Aitziber); Castilla, J. (Jesús); Juanbeltz, R. (Regina); Casado, I. (Itziar); Ezpeleta, C. (Carmen); Zozaya, J.M. (José Manuel)
    Background: The World Health Organization set targets to eliminate hepatitis C virus (HCV) infection through detection and treatment of all cases by 2030. This study aimed to describe the progress and difficulties in the elimination of HCV infection in Navarra, Spain. Methods: Using electronic healthcare databases, we performed a population-based prospective cohort study to describe changes in the prevalence of diagnosed active HCV infection at the beginning of 2015 and the end of 2017, the rate of new diagnoses and the rate of post-treatment viral clearance (PTVC) during this period. Results: At the beginning of 2015 there were 1503 patients diagnosed with positive HCV-RNA, 2.4 per 1000 inhabitants, and at the end of 2017 the prevalence had decreased by 47%. In the study period, 333 (18 per 100,000 person-years) new positive HCV-RNA cases were detected, but only 76 (23%; 4.2 per 100,000 person-years) did not have anti-HCV antibodies previously detected. Prevalent cases and new diagnoses of active infection were more frequent in men, people born in 1950-1979, HIV-infected patients and in those with lower income levels. Among patients with HCV-RNA, 984 achieved PTVC (22.7 per 100 person-years). PTVC was less frequent in patients born before 1940, in immigrants and in patients with lower income levels. Conclusions: The prevalence of diagnosed active HCV infection has dropped by almost half over three years, because the number of patients with PTVC was much higher than the number of new diagnoses. Interventions specifically targeted at population groups with less favourable trends may be necessary.
  • Thumbnail Image
    Detection of Respiratory Viruses in Deceased Persons, Spain, 2017
    (Centers for Disease Control and Prevention, 2018) Martínez-Baz, I. (Iván); Navascués, A. (Ana); Pérez-García, A. (Alejandra); Aguinaga, A. (Aitziber); Castilla, J. (Jesús); Floristan-Floristan, M.Y. (María Yugo); Casado, I. (Itziar); Ezpeleta, C. (Carmen)
    During the 2016–17 influenza season in Spain, we tested specimens from 57 elderly deceased persons for respira- tory viruses. Influenza viruses were detected in 18% of the specimens and any respiratory virus in 47%. Only 7% of participants had received a diagnosis of infection with the detected virus before death.